# Lantheus

Type: Company (LNTH)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/lantheus
Canonical HTML page: https://getbiobrief.com/entity/lantheus

## Recent coverage (2 stories)

### Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth
2026-02-26 22:32:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Full story: https://getbiobrief.com/story/q4-2025-biotech-earnings-analysis

### Natera and Lantheus Earnings: Precision Diagnostics and Radiopharma in Focus
2026-02-25 05:15:00 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.
Full story: https://getbiobrief.com/story/natera-lantheus-earnings-preview-biotech-diagnostics

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.